EP Patent

EP2389945A1 — Pharmaceutical composition comprising AVE0010 and insulin glargine

Assigned to Sanofi Aventis Deutschland GmbH · Expires 2011-11-30 · 14y expired

What this patent protects

Subject of the present invention is a pharmaceutical composition comprising (a) desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof.

USPTO Abstract

Subject of the present invention is a pharmaceutical composition comprising (a) desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number: EP2389945A1
Jurisdiction: EP
Classification: —
Expires: 2011-11-30
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis Deutschland GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.